NewAmsterdam Pharma Company NAMS Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from NewAmsterdam Pharma Company’s reported figures.
Based on trailing twelve months.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's return on assets?
- NewAmsterdam Pharma Company (NAMS) reported return on assets of -27.4% in Q1 2026.
- How has NewAmsterdam Pharma Company's return on assets changed year-over-year?
- NewAmsterdam Pharma Company's return on assets increased by 4.3% year-over-year, from -28.7% to -27.4%.
- What is the long-term trend for NewAmsterdam Pharma Company's return on assets?
- Over 2 years (2023 to 2025), NewAmsterdam Pharma Company's return on assets has grown at a -23.7% compound annual growth rate (CAGR), from -42.9% to -24.9%.
- What does return on assets mean?
- Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.